SL

Savaridoss Lidiyanayagi

Active Director Director DIN 09723955
DIN 09723955 First appointment Sep 2022 Primary industry Research & Development
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Savaridoss Lidiyanayagi

Data last updated:

Savaridoss Lidiyanayagi is a Director at Bacalt Biotech Private Limited (since 2022). The company operates in Research & Development.

DIN 09723955
Primary Designation Director
Industry Research & Development
First Appointment 01 Sep 2022
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Bacalt Biotech Private Limited U73100KA2022PTC165617
Director01 Sep 20222022Under Process Of Striking Off

Board colleagues of Savaridoss Lidiyanayagi

Directorship timeline

Open interactive timeline →
Bacalt Biotech Private Limited
Premium access

Shareholding and investment profile for Savaridoss Lidiyanayagi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Savaridoss Lidiyanayagi

Savaridoss Lidiyanayagi currently holds 1 directorship: Bacalt Biotech Private Limited (Director, since 01 Sep 2022).

Savaridoss Lidiyanayagi was first appointed on 01 Sep 2022 as Director at Bacalt Biotech Private Limited.

The current boards of Savaridoss Lidiyanayagi's companies include Kavitha Krishnamoorthy Karimangalam (Bacalt Biotech Private Limited), Shruti Ketan Kutmutia (Bacalt Biotech Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available